The US Food and Drug Administration (FDA) has given Sun Pharmaceuticals approval to market a generic version of UCB’s Keppra epilepsy injection.

The generic injection – levetiracetam – is used as an adjunctive therapy to treat partial onset seizures in adults with epilepsy and myoclonic seizures in patients with juvenile myoclonic epilepsy.

The injection, 100mg/ml packaged in 500mg/5ml single use vials, is equivalent to a 100 mg/ml Keppra injection.